

46-01

A

04/05/01



31093 U.S. 6

PTO/SB/13/PCT (10-03)  
Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION

DOCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION		PRIOR APPLICATION EXAMINER	ART UNIT
GA0150C	CLASS	SUBCLASS		

60928/06/05/01

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR 1.53(b) of pending prior international application Number PCT US99/23166, filed on 04 October 1999 entitled GENES DIFFERENTIALLY EXPRESSED IN CANCER CELLS TO DESIGN CANCER VACCINES, which designated the United States.

Note: 37 CFR 1.53(d) cannot be used to file a continuation or divisional application of an international application which has not entered the national stage.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS (37 CFR 1.16(c))	24 - 20 =	4	x 18 =	\$	72.00
INDEPENDENT CLAIMS (37 CFR 1.16(b))	5 - 3 =	2	x 80 =		160.00
MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(c))			+ 270 =		270.00
			BASIC FEE (37 CFR 1.16(a))	+	710.00
			Total of above Calculations =		1,212.00
			Reduction by 50% for filing by small entity (Note 37 CFR		0.00
			Total =		\$1,212.00

- Enclosed are the specification, claims and drawing(s).
- ☐ Applicant claims small entity status. See 37 CFR 1.27.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. 07-1074. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ \_\_\_\_\_ is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☒ Application Data Sheet is enclosed. See 37 CFR 1.76.
- ☒ Amend the specification by inserting before the first line the sentence: "This application is a ☒ continuation ☐ division of international application number PCT US99/23166, filed 04 October 1999 (status, abandoned, pending, etc.)."

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION**

8. ☒ A declaration under 37 CFR 1.63 is enclosed.
9. ☐ Priority of foreign application number \_\_\_\_\_, filed on \_\_\_\_\_ in \_\_\_\_\_  
is claimed under 35 U.S.C. 119(a)-(d).  
☐ The certified copy is enclosed.
10. ☐ A preliminary amendment is enclosed.
11. ☒ Also enclosed: **Return Postcard**

Address all future correspondence to: (May only be completed by applicant, or attorney or agent of record).

Elizabeth Lassen, Genzyme Corporation, 15 Pleasant Street Connector, P.O. Box 9322,  
Framingham, Massachusetts 01701-9322

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

4/5/01  
Date


Elizabeth Lassen  
Signature

Elizabeth Lassen  
Typed or printed name

- ☐ Inventor(s)/Applicant(s)
- ☐ Assignee of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).
- ☒ Attorney or agent of record
- ☐ Filed under 37 CFR 1.34(a)  
Registration number if acting under 37 CFR 1.34(a): \_\_\_\_\_

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☐ \*Total of \_\_\_\_\_ forms are submitted.

<b>CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)</b> Applicant(s): <b>ROBERTS, et al.</b>			Docket No. <b>GA0150C</b>	
Serial No. Unassigned	Filing Date <b>April 5, 2001</b>	Examiner Unassigned	Group Art Unit Unassigned	
Invention: <b>GENES DIFFERENTIALLY EXPRESSED IN CANCER CELLS TO DESIGN CANCER VACCINES</b>				
<p>I hereby certify that the following correspondence:</p> <div style="border: 1px solid black; padding: 5px; margin: 10px 0;"> <p><b>A Request for Filing a Continuation of an International Application under 37 CFR 1.53(b) (2 sheets); Application Data Sheet; Unexecuted Declaration for Utility or Design Patent Application (37 CFR 1.63) (3 sheets); a Patent Application (71 sheets); Formal Drawing (1 sheet); and a Return Postcard</b></p> </div> <p style="text-align: center;"><i>(Identify type of correspondence)</i></p> <p>is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on</p> <div style="display: flex; justify-content: space-between; margin-top: 20px;"> <div style="width: 40%;"> <p><b>April 5, 2001</b></p> <p><i>(Date)</i></p> </div> <div style="width: 50%; text-align: center;"> <p><b>TARYN ANTALEK</b></p> <p><i>(Typed or Printed Name of Person Mailing Correspondence)</i></p> <div style="margin: 10px 0;">  </div> <p><i>(Signature of Person Mailing Correspondence)</i></p> <div style="margin: 10px 0;"> <p><b>EL 826 463 585 US</b></p> <p><i>("Express Mail" Mailing Label Number)</i></p> </div> </div> </div>				
<p><b>Note: Each paper must have its own certificate of mailing.</b></p>				